Table 1. Clinical and treatment... | American Society of Hematology

Table 1.

Clinical and treatment characteristics

Clinical feature at diagnosis	No. patients	All patients	Percentage
Male sex	101	130	77.7
Stages III/IV	98	108	81.5
B symptoms	46	101	45.5
Bulk, 10 cm or more	22	90	24.4
Leukemic manifestation	47	99	47.5
IPI score 3-5	43	78	55.1
Bone marrow involvement	76	102	74.5
Palpable lymphadenopathy	79	103	76.7
Splenomegaly	60	101	59.4
Gastrointestinal involvement	24	102	23.5
LDH level elevated	32	86	37.2
Treatment
Treated	99	104	95.2
Chemotherapy	88	99	88.9
Polychemotherapy	77	88	87.5
Anthracycline	35	86	40.7
Single-agent therapy	11	88	12.5
Radiotherapy	15	99	15.2
Resection/splenectomy	18	99	18.2
CR after initial therapy	22	93	23.7
ASCT*	14	104	13.5

Clinical feature at diagnosis	No. patients	All patients	Percentage
Male sex	101	130	77.7
Stages III/IV	98	108	81.5
B symptoms	46	101	45.5
Bulk, 10 cm or more	22	90	24.4
Leukemic manifestation	47	99	47.5
IPI score 3-5	43	78	55.1
Bone marrow involvement	76	102	74.5
Palpable lymphadenopathy	79	103	76.7
Splenomegaly	60	101	59.4
Gastrointestinal involvement	24	102	23.5
LDH level elevated	32	86	37.2
Treatment
Treated	99	104	95.2
Chemotherapy	88	99	88.9
Polychemotherapy	77	88	87.5
Anthracycline	35	86	40.7
Single-agent therapy	11	88	12.5
Radiotherapy	15	99	15.2
Resection/splenectomy	18	99	18.2
CR after initial therapy	22	93	23.7
ASCT*	14	104	13.5

LDH indicates lactate dehydrogenase.

^†Median age of 111 patients was 63 years (quartiles: 55, 70).

High-dose chemotherapy and autologous stem cell transplantation (ASCT).